Pre-Clinical Pharmacokinetic Characterization, Tissue Distribution, and Excretion Studies of Novel Edaravone Oral Prodrug, TEJ-1704

Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) is a free radical scavenger approved for the treatment of amyotrophic lateral sclerosis, a fatal neuromuscular disease. Edaravone is administered as an intravenous infusion over 60 min for several treatment cycles. To ease the burden of patients and ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Dong Wook, Kim, Ju Hee, Kim, Kyung Min, Cho, Seok-jin, Jang, Hee-Woon, Chang, Ji Won, Dong, Seung Myung, Lim, Jee Woong, Kim, Jae-Sun, Cho, Hea-Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469431/
https://www.ncbi.nlm.nih.gov/pubmed/34575481
http://dx.doi.org/10.3390/pharmaceutics13091406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469431/
https://www.ncbi.nlm.nih.gov/pubmed/34575481
http://dx.doi.org/10.3390/pharmaceutics13091406

Ejemplares similares